Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

5 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
4(26.7%)
Phase 1
3(20.0%)
Phase 4
3(20.0%)
Phase 3
2(13.3%)
Phase 2
2(13.3%)
Early Phase 1
1(6.7%)
15Total
N/A(4)
Phase 1(3)
Phase 4(3)
Phase 3(2)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT05862051Not ApplicableActive Not Recruiting

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Role: collaborator

NCT07481175Phase 1Recruiting

Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

Role: collaborator

NCT06094140Phase 2Active Not Recruiting

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Role: collaborator

NCT05577416Early Phase 1Completed

A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Role: collaborator

NCT05668026Phase 1Recruiting

Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

Role: collaborator

NCT06881732Phase 1Not Yet Recruiting

Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP

Role: collaborator

NCT03806764Not ApplicableUnknown

Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient

Role: collaborator

NCT03691012Unknown

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

Role: lead

NCT04223674Not ApplicableUnknown

Serological Screen and Treat Trial for Plasmodium Vivax

Role: collaborator

NCT04122430Completed

Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours

Role: lead

NCT02605720Phase 3Completed

Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns

Role: collaborator

NCT00671138Phase 2Completed

Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity

Role: collaborator

NCT02364583Phase 4Unknown

Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection

Role: collaborator

NCT02143934Phase 4Completed

Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Role: collaborator

NCT01878357Phase 4Completed

Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine

Role: collaborator

NCT01837992Not ApplicableUnknown

Safety and Efficacy of Primaquine for P. Vivax

Role: collaborator

NCT01136850Phase 3Completed

Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea

Role: collaborator

All 17 trials loaded